Breaking News Instant updates and real-time market news.

GBT

Global Blood Therapeutics

$60.03

3.94 (7.02%)

07:51
11/26/19
11/26
07:51
11/26/19
07:51

Global Blood Therapeutics price target raised to $110 from $100 at SunTrust

SunTrust analyst Joon Lee raised his price target on Global Blood Therapeutics to $110 and kept his Buy rating, adjusting his model after yesterday's FDA decision to approve Oxbryta, formerly voxeltor, for SCD on an accelerated basis and "significantly" ahead of the Feb 26th PDUFA. The analyst notes that the label is "rather broad and consistent" with the trial demographics and efficacy/safety results that the company disclosed previously. Lee adds that the early approval "speaks to the significance" of the drug's value proposition in SCD.

  • 26

    Feb

GBT Global Blood Therapeutics
$60.03

3.94 (7.02%)

11/25/19
CANT
11/25/19
INITIATION
Target $98
CANT
Overweight
Global Blood Therapeutics assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young assumed coverage of Global Blood Therapeutics with an Overweight rating and $98 price target, down from $110. The analyst expects an early voxelotor approval, a "clean" label, and U.S. annual pricing in the neighborhood of $80,000-$100,000. She thinks U.S. voxelotor expectations of $46M in 2020 look reasonable.
11/26/19
PIPR
11/26/19
NO CHANGE
Target $95
PIPR
Overweight
Global Blood Therapeutics price target raised to $95 from $80 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target for Global Blood Therapeutics to $95 from $80 after Oxbryta received accelerated approval for sickle cell disease three months ahead of its FDA action date. Further, the drug's "non-restrictive" label includes all sickle cell patients 12 years old and older, Brill tells investors in a research note. She believes expectations for the launch are low and remains bullish. The analyst keeps an Overweight rating on Global Blood Therapeutics.
11/26/19
NOMU
11/26/19
NO CHANGE
Target $112
NOMU
Buy
Global Blood price target raised to $112 from $109 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Global Blood Therapeutics to $112 from $109 after the FDA approved Oxbryta for the treatment of sickle cell diseases in patients age 12 and older. The approval "includes the broadest possible label," Marai tells investors in a research note. He reiterates a Buy rating on Global Blood Therapeutics.
11/26/19
OPCO
11/26/19
NO CHANGE
Target $100
OPCO
Outperform
Global Blood price target raised to $100 from $94 at Oppenheimer
Oppenheimer analyst Mark Breidenbach raised his price target for Global Blood Therapeutics to $100 from $94 after Oxbryta received accelerated approval from the FDA, three months ahead of the action date. Oxbryta represents a new class of disease-modifying therapy, and could potentially become a therapeutic mainstay in sickle cell anemia, Breidenbach tells investors in a research note. Further, Oxbryta's "best-case" label includes adults and adolescents 12 years and older, adds the analyst. He keeps an Outperform rating on Global Blood shares.

TODAY'S FREE FLY STORIES

AQST

Aquestive Therapeutics

$7.89

-0.13 (-1.62%)

15:25
12/09/19
12/09
15:25
12/09/19
15:25
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

PTLA

Portola Pharmaceuticals

$28.48

-0.74 (-2.53%)

15:24
12/09/19
12/09
15:24
12/09/19
15:24
Hot Stocks
Portola presents new interim Phase 2a data from study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$19.72

10.045 (103.88%)

15:21
12/09/19
12/09
15:21
12/09/19
15:21
Downgrade
ArQule rating change  »

ArQule downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

TOL

Toll Brothers

$41.50

0.62 (1.52%)

15:19
12/09/19
12/09
15:19
12/09/19
15:19
Options
Toll Brothers options imply 8.6% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/09/19
12/09
15:17
12/09/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/09/19
12/09
15:16
12/09/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$33.53

-0.06 (-0.18%)

15:15
12/09/19
12/09
15:15
12/09/19
15:15
Options
Dish put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$9.87

0.19 (1.96%)

15:09
12/09/19
12/09
15:09
12/09/19
15:09
Hot Stocks
MacroGenics announces updated results from Phase 1/2 study of flotetuzumab »

MacroGenics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MDB

MongoDB

$131.13

-0.09 (-0.07%)

15:04
12/09/19
12/09
15:04
12/09/19
15:04
Options
MongoDB options imply 14.8% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 18

    Dec

IMGN

ImmunoGen

$4.06

0.195 (5.05%)

15:03
12/09/19
12/09
15:03
12/09/19
15:03
Hot Stocks
ImmunoGen presents updated findings from Phase 1 study of IMGN632 at ASH meeting »

ImmunoGen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/09/19
12/09
15:00
12/09/19
15:00
General news
U.S.-China trade/tariff uncertainty is still present »

U.S.-China trade/tariff…

NVS

Novartis

$92.68

0.6 (0.65%)

14:53
12/09/19
12/09
14:53
12/09/19
14:53
Hot Stocks
Novartis says Kymriah demonstrates consistent efficacy, safety outcomes »

Novartis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GILD

Gilead

$67.11

0.02 (0.03%)

14:51
12/09/19
12/09
14:51
12/09/19
14:51
Hot Stocks
Gilead's Kite says results ZUMA-2 trial support regulatory filings »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMDA

Gamida Cell

$5.10

0.01 (0.20%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Hot Stocks
Gamida Cell announces results from Phase 1 clinical study of GDA-201 »

Gamida Cell announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$25.05

0.92 (3.81%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Options
Stitch Fix options imply 24.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

GILD

Gilead

$67.08

-0.01 (-0.01%)

14:47
12/09/19
12/09
14:47
12/09/19
14:47
Hot Stocks
Gilead's Kite announces findings from ongoing post-marketing study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$17.55

-0.34 (-1.90%)

14:45
12/09/19
12/09
14:45
12/09/19
14:45
Options
Nuance call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:41
12/09/19
12/09
14:41
12/09/19
14:41
Periodicals
SoftBank taps Goldman for $1.75B financing to help revive WeWork, Bloomberg says »

SoftBank (SFTBF) has…

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 26

    Feb

CBL

CBL & Associates

$1.12

-0.025 (-2.18%)

14:36
12/09/19
12/09
14:36
12/09/19
14:36
Hot Stocks
CBL & Associates closes sale of interest in the Outlet Shoppes at Atlanta »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

14:25
12/09/19
12/09
14:25
12/09/19
14:25
Options
Berkshire Hathaway call volume above normal and directionally bullish »

Bullish option flow…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/09/19
12/09
14:17
12/09/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/09/19
12/09
14:16
12/09/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
12/09/19
12/09
14:15
12/09/19
14:15
General news
Treasury Action: yields are little changed »

Treasury Action: yields…

VWAGY

Volkswagen

$0.00

(0.00%)

14:08
12/09/19
12/09
14:08
12/09/19
14:08
Hot Stocks
Canada agency says VW charged with federal environmental law offences »

According to Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$88.77

-0.07 (-0.08%)

, ARQL

ArQule

$19.70

10.03 (103.72%)

14:07
12/09/19
12/09
14:07
12/09/19
14:07
Downgrade
Merck, ArQule rating change  »

ArQule downgraded to…

MRK

Merck

$88.77

-0.07 (-0.08%)

ARQL

ArQule

$19.70

10.03 (103.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 11

    Dec

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.